Nexalin Acquires Digital Health Platform Ahead of FDA Pivotal Trial for Insomnia Treatment
The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
